| Literature DB >> 29687313 |
Kristen Leppert1,2, Katharine Bisordi3, Jessica Nieto4, Kristin Maloney3, Yue Guan3, Shannan Dixon3, Alena Egense3.
Abstract
Newborn screening (NBS) is a public health program whose aim is to identify infants who will be clinically affected with a serious metabolic, genetic, or endocrine disorder; however, the technology utilized by many NBS programs also detects infants who are heterozygous carriers for autosomal recessive conditions. Discussion surrounding disclosure of these incidental carrier findings remains controversial. The purpose of this study was to assess genetic counselors' attitudes about disclosure of carrier status results generated by NBS and to gather data on their experiences with incidental carrier findings. An electronic survey was distributed to genetic counselors of all specialties via the NSGC listserv, and a total of 235 survey responses were analyzed. Quantitative data were analyzed using IBM SPSS v24, and qualitative data were manually analyzed for thematic analysis. Results show that the counselor participants were overall in favor of routine disclosure. Those with experience in NBS were much more likely to strongly agree with one or more reasons for disclosure (p < 0.001), whereas those with five or fewer years of experience were more likely to strongly agree with one or more reasons for non-disclosure (p = 0.031). Qualitative analysis identified key motivating factors for disclosure, including helping parents to understand a positive screen, parents may otherwise be unaware of reproductive risk and they may not otherwise have access to this information, and, while genetic testing is inherently a complex and ambiguous process, this does not justify non-disclosure. The main motivating factor for non-disclosure was the need for better counseling and informed consent. The data suggest that implementation of an "opt-in/out" policy for parents to decide whether or not to receive incidental findings would be beneficial. The results of this study support the continued disclosure of incidental carrier findings; however, additional research is necessary to further determine and implement the most effective disclosure practices.Entities:
Keywords: Carrier status; Genetic counselors; Heterozygous; Incidental findings; Newborn screening; Policy
Mesh:
Year: 2018 PMID: 29687313 PMCID: PMC6209045 DOI: 10.1007/s10897-018-0258-0
Source DB: PubMed Journal: J Genet Couns ISSN: 1059-7700 Impact factor: 2.537
Participant demographics
| Characteristic | Number | Percent | Characteristic | Number | Percent |
|---|---|---|---|---|---|
| Years experience | Age | ||||
| 0–1 year | 72 | 30.6 | 20–24 | 21 | 9 |
| 2–6 years | 84 | 35.7 | 25–29 | 93 | 39.9 |
| 7–11 years | 36 | 15.3 | 30–34 | 57 | 24.5 |
| 12–16 years | 20 | 8.5 | 35–39 | 26 | 11.2 |
| 17–21 years | 10 | 4.3 | 40–44 | 12 | 5.2 |
| 22–26 years | 6 | 2.6 | 45–49 | 7 | 3 |
| 27–31 years | 5 | 2.1 | 50–54 | 8 | 3.4 |
| 32–36 years | 2 | 0.9 | 55–59 | 4 | 1.7 |
| Valid total | 235 | 100 | 60–64 | 4 | 1.7 |
| Missing | 0 | 65–70 | 1 | 0.4 | |
| Total | 235 | Valid total | 233 | 100 | |
| Missing | 2 | ||||
| Sex | Total | 235 | |||
| Female | 224 | 95.7 | |||
| Male | 9 | 3.8 | Sees patients? | ||
| Prefer not to answer | 1 | 0.4 | Clinical counselor | 191 | 81.3 |
| Valid total | 234 | 100 | Non-clinical counselor | 44 | 18.7 |
| Missing | 1 | Valid total | 235 | 100 | |
| Total | 235 | Missing | 0 | ||
| Total | 235 | ||||
| Primary work setting (non-clinical) | |||||
| Commercial diagnostic laboratory | 22 | 51.2 | Primary work setting (clinical) | ||
| Academic Medical Center | 13 | 30.2 | Academic Medical Center | 81 | 42.6 |
| Private hospital/medical facility | 2 | 4.7 | Public hospital/medical facility | 47 | 24.7 |
| Public hospital/medical facility | 0 | 0 | Private hospital/medical facility | 40 | 21.1 |
| State health department | 0 | 0 | State health department | 10 | 5.3 |
| Other non-clinical counseling setting: | 6 | 14 | Commercial diagnostic laboratory | 6 | 3.2 |
| Research | 2 | Other clinical counseling setting: | 6 | 3.2 | |
| Non-profit | 2 | Non-profit | 4 | ||
| Gamete facility | 1 | NBS program | 1 | ||
| Health plan | 1 | Department of Veterans Affairs | 1 | ||
| Valid total | 43 | 100 | Valid total | 190 | 100 |
| Missing | 192 | Missing | 45 | ||
| Total | 235 | Total | 235 | ||
| NSGC regions | Narrow specialty categories | ||||
| Region 1 | 8 | 6.1 | Prenatal | 53 | 22.6 |
| Region 2 | 23 | 17.6 | Pediatric | 56 | 23.8 |
| Region 3 | 17 | 13 | Cancer | 40 | 17 |
| Region 4 | 42 | 32.1 | Other | 86 | 36.6 |
| Region 5 | 20 | 15.3 | Valid total | 235 | 100 |
| Region 6 | 18 | 13.7 | Missing | 0 | |
| Other | Total | 235 | |||
| London, UK | 3 | 2.3 | |||
| Australia | |||||
| Germany | |||||
| Valid total | 131 | Experience with either NBS follow-up or disclosure of incidental carrier findings | |||
| Missing | 104 | No | 107 | 45.5 | |
| Total | 235 | Yes | 128 | 54.5 | |
| Valid total | 235 | 100 | |||
| Missing | 0 | ||||
| Total | 235 | ||||
Current NBS practices reported by participants
| Number | Percent | |
|---|---|---|
| Does your state’s newborn screening program identify carriers of one or more genetic conditions via the initial screen and through follow-up diagnostic testing for an abnormal screen (for example: sickle-cell, cystic fibrosis, galactosemia, VLCAD deficiency)? | ||
| Yes | 184 | 79.7 |
| No | 3 | 1.3 |
| Unsure | 44 | 19 |
| Total | 231 | 100 |
| Missing | 4 | |
| Total | 235 | |
| In your state, are parents notified of carrier status information discovered by follow-up diagnostic testing after an abnormal screen result? | ||
| Yes—all | 55 | 30.4 |
| Yes—some | 19 | 10.5 |
| No | 2 | 1.1 |
| Unsure | 105 | 58 |
| Total | 181 | 100 |
| Missing | 54 | 23 |
| Total | 235 | 100 |
| Does your state’s newborn screening program have a protocol in place? | ||
| Yes | 62 | 34.3 |
| No | 9 | 5 |
| Unsure | 110 | 60.8 |
| Total | 181 | 100 |
| Missing | 54 | |
| Total | 235 | |
Fig. 1a Agreement with disclosure. b Overall, do you support or oppose routine disclosure of incidental carrier results secondary to newborn screening?
Fig. 2Agreement with non-disclosure
Fig. 3Left: Dissenting genetic counselors (strongly agreed with one or more reasons for non-disclosure) - percent (n); Right: assenting genetic counselors (strongly agreed with one or more reasons for disclosure) - percent (n)
Quantitative data thematic analysis
| Overall, do you support or oppose routine disclosure of incidental carrier results secondary to newborn screening, and why? | |
| Motivation for disclosure | Motivation for non-disclosure |
| Other notable points: | |
Participant opinions on newborn screening methodology
| Number | Percent | |
|---|---|---|
| Overall, would you support or oppose the implementation of molecular testing methods into all newborn screening programs, if it would result in more carriers being identified and if states would require disclosure of these results? | ||
| Support | 86 | 41.7 |
| Oppose | 66 | 32 |
| No opinion | 54 | 26.2 |
| Valid total | 206 | 100 |
| Missing | 29 | |
| Total | 235 | |
| Would you support or oppose the implementation of testing methods which do not detect carrier infants into newborn screening programs? | ||
| Support | 101 | 49 |
| Oppose | 31 | 15 |
| No opinion | 74 | 35.9 |
| Valid total | 206 | 100 |
| Missing | 29 | |
| Total | 235 | |
Fig. 4Perceived effectiveness of carrier status disclosure. a How often do you feel that disclosures are successful (meaning that effective counseling was completed, parental understanding was achieved, and the benefit of the disclosure justified the time/money/resources spent)? b How often did you feel that the client had a clear and complete understanding of the implications of carrier status? c Overall, do you believe that carrier information is beneficial or harmful for parents to learn?